2 recruiting, 1 active not recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Treatment pause: new trials by email Literature Review of Treatment pause trials Research Report on Treatment pause
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk PD-1/PD-L1 ICI + VEGFR-TKI, Treatment pause - Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Jinling Hospital, China | 75 | 2026-06-16 | 2026-08-11 |
| PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk Intermittent PD-1/PD-L1 ICI + VEGFR-TKI - Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC) | Phase 2 | Recruiting | Jinling Hospital, China | 30 | 2025-01-24 | 2025-09-16 |
| Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors Combination PD-1/PD-L1 ICI + VEGFR-TKI, Treatment pause - Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score | Phase 3 | Active not recruiting | University Hospital, Bordeaux | 22 | 2023-01-23 | 2025-06-04 |
Carcinoma, Renal Cell (2) · Clear-cell metastatic renal cell carcinoma (1)
Jinling Hospital, China (2) · University Hospital, Bordeaux (1)
China (2) · France (1)
Le Qu (1) · Le Qu, Ph.D. (1)